๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-05-13

A1Cantus vs. Placebo (NCT07585630)

Double-Blind Randomized Controlled Trial of A1Cantus Drink vs. Placebo for Reduction of Ha1c

๐ŸŸก Not Yet Recruiting Phase2 ๐Ÿ“‹ Clinical Research Protocol Sponsor: University of California, Riverside

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.

Who can join: Review the eligibility criteria below.

Location: UCR Health โ€” Riverside, California

Age range: 21 Years to 75 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • UCR Health โ€” Riverside, California

๐Ÿ“ž Contact the Study Coordinator

Phone: (951) 827-8643

Email: elizabeth.jacobs@medsch.ucr.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Type 2 Diabetes clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—